Major depressive disorder has traditionally been treated with anti-depressants. However, research demonstrates that anti-depressants have failed to achieve satisfactory results for many patients.

The patented breakthrough technology of BrainswayTM unfolds a new dawn in depression treatment. The company offers a clinically-proven solution for various categories of depression patients, ranging from mild to severe depression cases, who failed to achieve sufficient outcomes from existing treatments in the current episode.

The treatment performs deep non-invasive brain stimulation using directed electromagnetic fields, generating significant improvement in the depressive symptoms.

Brainsway’s technology is based on patents filed by the U.S. National Institutes of Health (NIH) and the company. The treatment has been enthusiastically embraced by the international academic community, with over 60 clinical trials in leading institutions worldwide, for psychiatric and neurological indications.
Effective, Well Tolerated Solution

Brainsway Deep TMS has many advantages over traditional depression treatments. The efficacy of antidepressants decreases with the number of failed medication trials\(^1\), and they also entail systemic side effects\(^2\) which lead many patients to neglect their medication regime. Other alternatives, such as Electroconvulsive Therapy (ECT), require anesthesia and may entail significant risks and side effects, while Surface TMS (Transcranial Magnetic Stimulation)\(^3\) is more limited in its ability to stimulate deep cortical areas\(^4\).

Therefore, in many cases, depression patients have been virtually trapped in their condition with limited solutions. Brainsway’s novel Deep TMS (Deep Transcranial Magnetic Stimulation) technology holds a variety of benefits for depression patients. In addition to its noninvasive stimulation of deep brain regions and high efficacy, the treatment involves no hospitalization, typically requiring only brief 20-minute daily sessions over a period of 4-5 weeks.

Clinical trials that led to Brainsway’s FDA clearance demonstrated excellent results using 33% less treatment sessions, with sessions which are almost 50% shorter than other forms of TMS technology.

Moreover, Deep TMS has no systemic side effects\(^5\)\(^-\)\(^8\)\(^,\)\(^10\). It is also highly convenient, as it can be administered in clinics of any size.

Clinically Proven, Certified and Safe

The FDA\(^9\) and the CE have approved Brainsway Deep TMS for treatment of a wide range of patients, suffering from mild to severe and persistent depression, who did not improve following the use of any number of antidepressants (in the current depressive episode).

The FDA indication is based on a unique long-term 16-week double-blind placebo-controlled multi-center study which enrolled over 230 subjects, showing a profound decline in HDRS-21 and significant remission (32.6%) and response (38.4%) rates at the primary endpoint of the study. In the study, Brainsway’s treatment was proven to be safe, and the treatment was well tolerated by the majority of the study subjects\(^10\).

---

\(^9\) FDA 510(k) No. K122288

* The Deep TMS depression treatment and surface TMS depression treatment were not compared in head-to-head studies.

---

Brainsway and the Brainsway logo are trademarks of Brainsway Ltd. © 2015 Brainsway. All Rights Reserved
For more information, scan the QR code or visit www.brainsway.com.
Tel: 1-855-200-DTMS | Email: info@brainsway.com